Urinary VP1 Flow Cytometry as a Complementary Approach for BK Polyomavirus Monitoring: A Proof-Of-Concept Study
Transplant International · 08.04.2026 · 39
DOI: 10.3389/ti.2026.15780 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant International, online erschienen am 08.04.2026. Verfasst von Haris Omic und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: BK Virus, Flow Cytometry, Polyomavirus Infections, Kidney Transplantation. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Polyomavirus nephropathy (BKPyVAN) is a major cause of allograft dysfunction after kidney transplantation (KTX). While plasma BKPyV-PCR is the diagnostic gold standard, it may not fully reflect tissue injury. We conducted a prospective observational proof-of-concept study in 30 KTX recipients with BKPyV reactivation (November 2022–February 2024); 21 underwent kidney biopsy, 11 were diagnosed with biopsy-proven (BP)-BKPyVAN. Urine samples were analyzed by flow cytometry to quantify the potential of VP1-positive reno-urinary epithelial cells as a novel non-invasive marker of active tubular damage. The control cohort included 21 virology-negative patients. Median urinary VP1-positivity was higher in BP-BKPyVAN (33%, IQR 27–46) vs. non-BKPyVAN patients (5%, IQR 1–13; p < 0.001). The assay achieved an AUC of 0.98 (95% CI 0.93–1.00, p = 0.0003; cut-off: 11.7%; sensitivity = 91%, specificity = 89%) for BP-BKPyVAN. Longitudinally, median VP1-burden declined from 13% (IQR 4–29) at baseline to 0% (IQR 0–0.4). BKPyV-DNAemia declined rapidly, but plateaued at ∼4 × 10 2 –7 × 10 2 copies/mL, whereas urinary VP1-positive cells became undetectable. Our preliminary results suggest that combining urinary VP1-positivity with plasma BKPyV-PCR may help distinguish BP-BKPyVAN from non-BKPyVAN within a BKPyV-reactivation cohort. Longitudinal VP1 tracking may indicate resolution of viral infection earlier than DNAemia. These findings are hypothesis-generating and require validation in larger independent cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
- Department of Clinical Virology, Medical University of Vienna, Vienna, Austria.
Zitieren
APA
Omic, H., Vecsei, D., Eder, M., Abd El-Ghany, K., Winnicki, W., Schmidt, A., Kapps, S., Gerges, D., Strassl, R., Wagner, L., & Eskandary, F. (2026). Urinary VP1 Flow Cytometry as a Complementary Approach for BK Polyomavirus Monitoring: A Proof-Of-Concept Study. Transplant International, 39. https://doi.org/10.3389/ti.2026.15780
Vancouver
Omic H, Vecsei D, Eder M, Abd El-Ghany K, Winnicki W, Schmidt A, et al. Urinary VP1 Flow Cytometry as a Complementary Approach for BK Polyomavirus Monitoring: A Proof-Of-Concept Study. Transplant International. 2026;39. doi:10.3389/ti.2026.15780
BibTeX
@article{Omic2026,
author = {Omic, Haris and Vecsei, David and Eder, Michael and Abd El-Ghany, Karim and Winnicki, Wolfgang and Schmidt, Alice and Kapps, Sebastian and Gerges, Daniela and Strassl, Robert and Wagner, Ludwig and Eskandary, Farsad},
title = {Urinary VP1 Flow Cytometry as a Complementary Approach for BK Polyomavirus Monitoring: A Proof-Of-Concept Study},
journal = {Transplant International},
year = {2026},
volume = {39},
doi = {10.3389/ti.2026.15780}
}
EUVIMED